All In Biotech

Drug Trial Radar · NCT06204809

Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

A Phase 1 Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of PGN-EDODM1 in Adult Participants With Myotonic Dystrophy Type 1 (FREEDOM-DM1)

Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Dec 12, 2023

Primary completion

Oct 28, 2025

Study completion Oct 28, 2025

Sponsor

Lead sponsor
PepGen IncIndustry
Sponsor type
Industry
First posted
Jan 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 2 periods: A Screening Period (up to 30 days) and a Treatment and Observation Period (16 weeks).

Conditions

  • Myotonic Dystrophy 1

Interventions

  • PGN-EDODM1 for infusionDrug

    Single dose of PGN-EDODM1 by intravenous (IV) infusion

  • PlaceboOther

    Administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events, Serious Adverse Events, with abnormal Clinical Laboratory tests, abnormal ECGs, and abnormal Vital SignsTime frame: Baseline to Week 16

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • UCI Center for Clinical Research

    Irvine, California

  • Stanford University

    Palo Alto, California

  • Rare Disease Research

    Atlanta, Georgia

  • University of Kansas Medical Center

    Fairway, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Rochester Medical Center

    Rochester, New York

  • Virginia Commonwealth University

    Richmond, Virginia

  • University of Calgary

    Calgary, Alberta, Canada

  • Ottawa Hospital Research Institute (OHRI)

    Ottawa, Ontario, Canada

  • CIUSSS du Saguenay-Lac-Saint-Jean

    Chicoutimi, Quebec, Canada

  • Salford Royal Hospital

    Salford, United Kingdom

  • University College London Hospital

    London, UK, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.